{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:37:15Z","timestamp":1792859835564,"version":"4.5.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.autrev.2026.104163","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:06:36Z","timestamp":1785996396000},"page":"104163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Idiopathic inflammatory myopathies as a damage\u2013data\u2013endotype continuum: A roadmap to precision trials and computable biomarkers"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7001-6532","authenticated-orcid":false,"given":"Sebastiano","family":"Gangemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7524-0103","authenticated-orcid":false,"given":"Luca","family":"Gammeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-1849","authenticated-orcid":false,"given":"Eleonora","family":"Longhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-7902","authenticated-orcid":false,"given":"Dimitrios","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-2252","authenticated-orcid":false,"given":"Maria Giovanna","family":"Danieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104163_bb0005","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMra2415426","article-title":"Inflammatory myopathies","volume":"394","author":"Allenbach","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/B978-0-323-90887-0.00008-0","article-title":"Immunotherapies in autoimmune inflammatory myopathies: rationale and therapeutic updates","volume":"214","author":"G R, MC D.","year":"2026","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.autrev.2026.104163_bb0015","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104163_bb0020","first-page":"74","article-title":"Item selection for the development and validation of a revised classification criteria for adult and juvenile idiopathic inflammatory myopathies: MyoROC project","author":"Saygin","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104163_bb0025","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","article-title":"Idiopathic inflammatory myopathies: current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0030","first-page":"39","article-title":"Emerging therapies in idiopathic inflammatory myopathies: advances in treatment and future directions","author":"Gallay","year":"2025","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0040","first-page":"13","article-title":"Detection of myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies","author":"Ghirardello","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.autrev.2026.104163_bb0045","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/rheumatology\/kead110","article-title":"Performance of the 2016 ACR-EULAR myositis response criteria in adult dermatomyositis\/polymyositis therapeutic trials and consensus profiles","volume":"62","author":"Saygin","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0050","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European league against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104163_bb0055","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/acr.25347","article-title":"2023 American College of Rheumatology (ACR)\/American College of CHEST Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2026.104163_bb0060","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated Cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0065","first-page":"78","article-title":"Prognostic significance of 1-year pulmonary function changes in inflammatory myopathy-related interstitial lung disease","author":"Keret","year":"2026","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104163_bb0070","first-page":"368","article-title":"Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trials","volume":"44","author":"Rivero Gallegos","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0075","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/trf.17766","article-title":"Autoantibody profiles in intravenous immunoglobulin preparations: a possible cause of mistaken autoimmunity diagnosis","volume":"64","author":"Miyamoto","year":"2024","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.autrev.2026.104163_bb0080","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0090","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1002\/art.23963","article-title":"Reliability and validity of the myositis disease activity assessment tool","volume":"58","author":"Sultan","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.autrev.2026.104163_bb0095","first-page":"11","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient\/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)\/childhood health assessment questionnaire (C-HAQ)","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2026.104163_bb0100","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0105","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104163_bb0110","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung diseaseDeveloped by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the euro\u2026","author":"Antoniou","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2026.104163_bb0115","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1093\/rheumatology\/kead122","article-title":"Quantitative interstitial lung disease scores in idiopathic inflammatory myopathies: longitudinal changes and clinical implications","volume":"62","author":"Yeo","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/art.43038","article-title":"Clinical characteristics of anti-Synthetase syndrome: analysis from the classification criteria for anti-synthetase syndrome project","volume":"77","author":"Faghihi-Kashani","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0125","first-page":"77","article-title":"Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria","author":"Cavagna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104163_bb0130","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/1756-185X.14664","article-title":"Predictive factors for progressive fibrosing interstitial lung disease in anti-synthetase syndrome","volume":"26","author":"Zhao","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104163_bb0135","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10067-023-06570-3","article-title":"Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease","volume":"42","author":"Fu","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0140","doi-asserted-by":"crossref","first-page":"186","DOI":"10.31138\/mjr.30.3.186","article-title":"Interstitial lung disease in anti-Synthetase syndrome","volume":"30","author":"Kourkouni","year":"2019","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","article-title":"Clinical features and outcomes of interstitial lung disease in anti-jo-1 positive antisynthetase syndrome","volume":"118","author":"Zamora","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0150","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.rmed.2009.05.001","article-title":"Anti-synthetase syndrome in ANA and anti-jo-1 negative patients presenting with idiopathic interstitial pneumonia","volume":"103","author":"Fischer","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0155","first-page":"20","article-title":"Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody","author":"Sclafani","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.autrev.2026.104163_bb0160","first-page":"9","article-title":"A new predictive model for the prognosis of MDA5+ DM-ILD","author":"Niu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2026.104163_bb0165","first-page":"9","article-title":"A matrix prediction model for the 6-month mortality risk in patients with anti-melanoma differentiation-associated Protein-5-positive dermatomyositis","author":"Ouyang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2026.104163_bb0170","first-page":"8","article-title":"A computed tomography Radiomics-based prediction model on interstitial lung disease in anti-MDA5-positive dermatomyositis","author":"Xu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2026.104163_bb0175","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1093\/rheumatology\/keab616","article-title":"Corrigendum to: a systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0180","doi-asserted-by":"crossref","first-page":"200","DOI":"10.31138\/mjr.300525.iao","article-title":"Clinical profile and outcomes in anti-TIF1\u03b3 positive idiopathic inflammatory myositis patients: a Greek cohort study","volume":"36","author":"Syrmou","year":"2025","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0185","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/rheumatology\/keac288","article-title":"ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis","volume":"61","author":"Selickaja","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0190","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/annrheumdis-2020-218661","article-title":"Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1\u03b3 can result in experimental myositis","volume":"80","author":"Okiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104163_bb0195","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0200","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-\u03b3 antibody and cancer-associated myositis: a clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104163_bb0205","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-021-08920-y","article-title":"An Italian multicenter study on anti-NXP2 antibodies: clinical and serological associations","volume":"63","author":"Fredi","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2026.104163_bb0210","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104163_bb0215","first-page":"19","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104163_bb0220","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1093\/rheumatology\/kead154","article-title":"Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature","volume":"62","author":"Demortier","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0225","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/rheumatology\/kev247","article-title":"High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis","volume":"54","author":"Muro","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0230","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.rdc.2025.07.014","article-title":"The spectrum of myocardial disease in idiopathic inflammatory myopathies","volume":"51","author":"Calhoun","year":"2025","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.autrev.2026.104163_bb0235","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.2147\/JIR.S503928","article-title":"Cardiac involvement in idiopathic inflammatory myopathies","volume":"18","author":"Zhu","year":"2025","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.autrev.2026.104163_bb0240","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/rheumatology\/keae029","article-title":"Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests","volume":"63","author":"Sen","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0245","first-page":"93","article-title":"Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: a narrative review","author":"Tison","year":"2026","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2026.104163_bb0250","first-page":"410","article-title":"Neurological adverse events of immune checkpoint inhibitors: a practical guide to diagnosis with a focus on neuroimaging findings","author":"Rossi","year":"2026","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2026.104163_bb0255","first-page":"140","article-title":"Immune checkpoint inhibitor-related neurotoxicity: incidence and management. A systematic review and meta-analysis","author":"Nielsen","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.autrev.2026.104163_bb0260","article-title":"Outcomes in patients with immune checkpoint inhibitor-related myopathy and prolonged follow-up","volume":"12","author":"Segal","year":"2025","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/j.autrev.2026.104163_bb0265","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00415-023-12134-x","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series","volume":"271","author":"Vicino","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2026.104163_bb0270","first-page":"131","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104163_bb0275","first-page":"11","article-title":"How should immune checkpoint inhibitor myocarditis be treated?","author":"Badaan","year":"2025","journal-title":"Cardiooncology"},{"key":"10.1016\/j.autrev.2026.104163_bb0280","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1093\/rheumatology\/keaf356","article-title":"The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature","volume":"64","author":"Nagra","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0285","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0290","first-page":"4","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2026.104163_bb0295","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0300","first-page":"17","article-title":"Immune-mediated necrotizing myopathy: a systematic review of antibody-specific mechanisms and treatment outcomes","author":"Vaezi","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2026.104163_bb0305","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16\u201318 June 2023, Hoofddorp, the Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2026.104163_bb0310","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.26859","article-title":"Long-term strength and functional status in inclusion body myositis and identification of trajectory subgroups","volume":"62","author":"Oldroyd","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2026.104163_bb0315","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0320","article-title":"Emerging therapies in idiopathic inflammatory myopathies","author":"Kocyigit","year":"2025","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2026.104163_bb0325","first-page":"8","article-title":"Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies","author":"Raaphorst","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2026.104163_bb0330","article-title":"Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies","volume":"8","author":"Raaphorst","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2026.104163_bb0335","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3899\/jrheum.2024-1115","article-title":"Role of CD19 chimeric antigen receptor T cell therapy in idiopathic inflammatory myopathies","volume":"52","author":"Aggarwal","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0340","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0345","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aea9007","article-title":"Dermatomyositis is characterized by JAK1-mediated monocyte-driven vasculopathy and inflammation","volume":"17","author":"Osborne","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0350","first-page":"22","article-title":"The interferon in idiopathic inflammatory myopathies: different signatures and new therapeutic perspectives. A literature review","author":"Gasparotto","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104163_bb0355","first-page":"31","article-title":"The role of interferons type I, II and III in myositis: a review","author":"Bolko","year":"2021","journal-title":"Brain Pathol"},{"key":"10.1016\/j.autrev.2026.104163_bb0360","first-page":"23","article-title":"The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis","author":"Castellini","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104163_bb0365","first-page":"15","article-title":"Dysregulated type I\/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis","author":"Yoshida","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104163_bb0370","first-page":"15","article-title":"Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: a single-arm systemic meta-analysis","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104163_bb0375","first-page":"394","article-title":"A phase 3 trial of Brepocitinib in dermatomyositis","author":"Vleugels","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0380","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMe2604009","article-title":"A phase 3 trial of Brepocitinib in dermatomyositis","volume":"394","author":"Lundberg","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0385","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/rheumatology\/kez664","article-title":"British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary","volume":"59","author":"MacKie","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0390","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-323-90887-0.00014-6","article-title":"Role of complement in neurologic autoimmunities: why need to target complement activation for effective immunotherapy","volume":"214","author":"Dalakas","year":"2026","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.autrev.2026.104163_bb0395","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/1744666X.2022.2054803","article-title":"Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104163_bb0400","first-page":"15","article-title":"Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104163_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1560483","article-title":"Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy","volume":"16","author":"Peng","year":"2025","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104163_bb0410","first-page":"13","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104163_bb0415","first-page":"15","article-title":"Single-cell profiling of muscle-infiltrating T cells in idiopathic inflammatory myopathies","author":"Argyriou","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0420","first-page":"21","article-title":"Alarmins in autoimmune diseases","author":"Danieli","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104163_bb0425","first-page":"27","article-title":"Enhanced systemic oxidative stress response in patients with idiopathic inflammatory myopathies","author":"Miko\u0142ajczyk-Korona","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104163_bb0430","first-page":"22","article-title":"Oxidative stress, mitochondrial dysfunction, and respiratory chain enzyme defects in inflammatory myopathies","author":"Danieli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104163_bb0435","first-page":"68","article-title":"Integrating machine learning into myositis research: a systematic review","author":"Juarez-Gomez","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2026.104163_bb0440","first-page":"21","article-title":"A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases","author":"Danieli","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104163_bb0445","first-page":"22","article-title":"A machine learning analysis to evaluate the outcome measures in inflammatory myopathies","author":"Danieli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104163_bb0450","doi-asserted-by":"crossref","DOI":"10.1002\/acr.80032","article-title":"Standardized interoperable data collection for myositis research: developing expert consensus on common data elements for myositis outcome measures","author":"Saygin","year":"2026","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2026.104163_bb0455","first-page":"354","article-title":"Brepocitinib, a potent and selective TYK2\/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis","volume":"43","author":"Paik","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0460","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104163_bb0465","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2026.103536","article-title":"Anti-MDA5 monoclonal antibodies from patients with dermatomyositis - B cell characteristics and differential targeting of the helicase domains","volume":"159","author":"Van Gompel","year":"2026","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104163_bb0475","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-Po","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104163_bb0480","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40674-021-00186-x","article-title":"Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease","volume":"7","author":"Selva-O\u2019Callaghan","year":"2021","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0485","first-page":"65","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2026.104163_bb0490","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2026.104163_bb0495","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","article-title":"Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile","volume":"181","author":"Preu\u00dfe","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2026.104163_bb0500","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/mus.28333","article-title":"Effectiveness and safety of IVIG for the treatment of HMGCR immune-mediated necrotizing myopathy","volume":"71","author":"Suh","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2026.104163_bb0505","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/acr.25406","article-title":"Benefits of early versus late initiation of intravenous immunoglobulin in the treatment of patients with Anti-3-Hydroxy-3-Methylglutaryl-coenzyme a reductase immune-mediated necrotizing myopathy","volume":"76","author":"Sharf","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2026.104163_bb0510","first-page":"22","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104163_bb0515","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0520","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.28114","article-title":"Management of immune-mediated necrotizing myopathy","volume":"70","author":"Suh","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2026.104163_bb0525","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/25785826.2022.2060169","article-title":"Immune-mediated necrotizing myopathy which showed deposition of C5b-9 in the necrotic muscle fibers and was successfully treated with intensive combined therapy with high-dose glucocorticoids, tacrolimus, and intravenous immunoglobulins","volume":"45","author":"Shimada","year":"2022","journal-title":"Immunol Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0530","first-page":"26","article-title":"Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome","author":"Narv\u00e1ez","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104163_bb0535","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3899\/jrheum.190505","article-title":"Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study","volume":"47","author":"Langlois","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0540","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0545","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/keae403","article-title":"Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review","volume":"64","author":"Kouranloo","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0550","doi-asserted-by":"crossref","first-page":"309","DOI":"10.55563\/clinexprheumatol\/8xj0b9","article-title":"Defining anti-synthetase syndrome: a systematic literature review","volume":"40","author":"Zanframundo","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0555","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome \u2013 much more than just a myopathy","volume":"51","author":"Opinc","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104163_bb0560","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.21037\/jtd-20-3328","article-title":"A narrative review of interstitial lung disease in anti-synthetase syndrome: a clinical approach","volume":"13","author":"Sawal","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.autrev.2026.104163_bb0565","first-page":"25","article-title":"A review of Antisynthetase syndrome-associated interstitial lung disease","author":"Patel","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104163_bb0570","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.ard.2025.01.050","article-title":"The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project","volume":"84","author":"Zanframundo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104163_bb0575","first-page":"277","article-title":"Agreement between local and central anti-synthetase antibodies detection: results from the classification criteria of anti-Synthetase syndrome project biobank","volume":"42","author":"Loganathan","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0580","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0585","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1378\/chest.08-2233","article-title":"Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature","volume":"135","author":"Kalluri","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2026.104163_bb0590","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MD.0b013e318260977c","article-title":"Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature","volume":"91","author":"Labirua-Iturburu","year":"2012","journal-title":"Medicine"},{"issue":"Suppl. 134","key":"10.1016\/j.autrev.2026.104163_bb0595","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single Centre cohort study","volume":"40","author":"Bozzalla-Cassione","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2026.102140","article-title":"Chimeric antigen receptor T-cell (CAR-T) therapy and other cellular immunotherapy treatments for idiopathic inflammatory myopathies","author":"Paul","year":"2026","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0605","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/s10165-010-0371-x","article-title":"Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis","volume":"21","author":"Gono","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0610","first-page":"45","article-title":"Serum ferritin as a specific biomarker of anti-MDA5-interstitial lung disease: a multicenter, case-control study in observational and validation datasets","author":"Conticini","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104163_bb0615","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104163_bb0620","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/mus.20958","article-title":"Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity","volume":"37","author":"Jackson","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2026.104163_bb0625","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0630","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1474-4422(23)00275-2","article-title":"Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Machado","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104163_bb0635","first-page":"11","article-title":"Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review","author":"Santos","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104163_bb0640","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104163_bb0645","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0650","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.autrev.2026.104163_bb0655","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104163_bb0660","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2020.01.002","article-title":"The validity and utility of the cutaneous disease area and severity index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review","volume":"50","author":"Ahmed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104163_bb0665","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0670","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of Bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0675","doi-asserted-by":"crossref","unstructured":"Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. BMJ 2020;370. doi:https:\/\/doi.org\/10.1136\/BMJ.M3164.","DOI":"10.1136\/bmj.m3164"},{"key":"10.1016\/j.autrev.2026.104163_bb0680","first-page":"370","article-title":"Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension","author":"Rivera","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104163_bb0685","first-page":"388","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104163_bb0690","first-page":"389","article-title":"SPIRIT 2025 Explanation and elaboration: updated guideline for protocols of randomised trials","author":"Hr\u00f3bjartsson","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104163_bb0695","first-page":"385","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104163_bb0700","first-page":"11","article-title":"Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence","author":"Collins","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2026.104163_bb0705","first-page":"202","article-title":"The myositis clinical trials consortium: an international collaborative initiative to promote clinical trials in adult and juvenile myositis","volume":"43","author":"Bishnoi","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0710","first-page":"178","article-title":"Shared governance of international myositis networks","volume":"44","author":"Liewluck","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0715","first-page":"3","article-title":"The future of digital health with federated learning","author":"Rieke","year":"2020","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0720","first-page":"5","article-title":"Federated machine learning in healthcare: a systematic review on clinical applications and technical architecture","author":"Teo","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0725","first-page":"101","article-title":"From challenges and pitfalls to recommendations and opportunities: implementing federated learning in healthcare","author":"Li","year":"2025","journal-title":"Med Image Anal"},{"key":"10.1016\/j.autrev.2026.104163_bb0730","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104163_bb0735","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/sim.10077","article-title":"A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling","volume":"43","author":"Wei","year":"2024","journal-title":"Stat Med"},{"key":"10.1016\/j.autrev.2026.104163_bb0740","first-page":"7","article-title":"Correlation analysis of quantitative MRI measurements of thigh muscles with histopathology in patients with idiopathic inflammatory myopathy","author":"Wang","year":"2023","journal-title":"Eur Radiol Exp"},{"key":"10.1016\/j.autrev.2026.104163_bb0745","first-page":"198","article-title":"Fat-corrected T2 measurement as a marker of active muscle disease in inflammatory myopathy","author":"Yao","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.autrev.2026.104163_bb0750","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1007\/s00415-024-12191-w","article-title":"Quantitative whole-body muscle MRI in idiopathic inflammatory myopathies including polymyositis with mitochondrial pathology: indications for a disease spectrum","volume":"271","author":"Zierer","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2026.104163_bb0755","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1007\/s00330-021-08411-w","article-title":"Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies","volume":"32","author":"Laporte","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.autrev.2026.104163_bb0760","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejrad.2019.01.024","article-title":"Automated CT quantification methods for the assessment of interstitial lung disease in collagen vascular diseases: a systematic review","volume":"112","author":"van Royen","year":"2019","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.autrev.2026.104163_bb0765","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.autrev.2026.104163_bb0770","first-page":"25","article-title":"Radiomics based on HRCT can predict RP-ILD and mortality in anti-MDA5 + dermatomyositis patients: a multi-center retrospective study","author":"He","year":"2024","journal-title":"Respir Res"},{"key":"10.1016\/j.autrev.2026.104163_bb0775","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0780","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0785","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2026.104163_bb0790","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104163_bb0795","first-page":"18","article-title":"Emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications","author":"Murdaca","year":"2019","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:02:24Z","timestamp":1792857744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":159,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1568997226001771"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104163","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idiopathic inflammatory myopathies as a damage\u2013data\u2013endotype continuum: A roadmap to precision trials and computable biomarkers","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104163"}}